Christiane J. Bruns
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christiane J. Bruns has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Karl-Walter Jauch
University of Munich
7 shared publicationsK.-W. Jauch
Chirurgische Klinik und Poliklinik, Campus Großhadern, Klinikum der Universität München, Deutschland
5 shared publicationsHanno Niess
University of Munich
4 shared publicationsClaudius Conrad
Massachusetts General Hospital
3 shared publicationsH. Nieß
Chirurgische Klinik und Poliklinik, Campus Großhadern, Klinikum der Universität München, Deutschland
3 shared publicationsIvan Ischenko
3 shared publications
Latest Publications
- 1 April 2015
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 26 (4) , 371-378
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib
The aim of this study was to investigate the impact of different KRAS mutations on the inhibitory potential of afatinib and gefitinib in SW48 colorectal cancer cells. The influence of afatinib/gefitinib on cell viability and cell cycle was evaluated in isogenic SW48 KRAS wild-type/mutant cells. Protein levels of phosphorylated/total EGFR, HER-2, HER-3, ERK, and AKT were compared between treated/untreated samples using western blotting. The activity of both afatinib and gefitinib was the lowest in KRAS G12C/G12S/G12D and the highest in G13D/G12A mutant subtypes. A 50% decrease in cell viability was achieved at concentrations of 3.0-7.7 μmol/l for afatinib and 5.4-19.5 μmol/l for gefitinib. The effect of both drugs on apoptosis appeared to be stronger than their influence on proliferation and was generally less pronounced in mutant cells than in wild-type cells. The average number of apoptotic cells after treatment with afatinib was 2.6 times as high as the corresponding value following treatment with gefitinib (P<0.01). Levels of pEGFR, pHER-2, pERK, and pAKT were reduced more extensively by afatinib than by gefitinib (P<0.001). Some KRAS mutations (G12C/G12S/G12D) appear to weaken the activity of afatinib and gefitinib whereas others seem to increase sensitivity to treatment (G13D/G12A) compared with the parental clone (KRAS wild-type). In SW48 colorectal cancer cells, afatinib seems to be more potent than gefitinib because of its superior efficacy in inhibiting both EGFR and HER-2, suppressing signaling along both MEK/ERK and PI3K/AKT pathways to a greater extent.
- 1 April 2015
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 26 (4) , 371-378
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib
The aim of this study was to investigate the impact of different KRAS mutations on the inhibitory potential of afatinib and gefitinib in SW48 colorectal cancer cells. The influence of afatinib/gefitinib on cell viability and cell cycle was evaluated in isogenic SW48 KRAS wild-type/mutant cells. Protein levels of phosphorylated/total EGFR, HER-2, HER-3, ERK, and AKT were compared between treated/untreated samples using western blotting. The activity of both afatinib and gefitinib was the lowest in KRAS G12C/G12S/G12D and the highest in G13D/G12A mutant subtypes. A 50% decrease in cell viability was achieved at concentrations of 3.0-7.7 μmol/l for afatinib and 5.4-19.5 μmol/l for gefitinib. The effect of both drugs on apoptosis appeared to be stronger than their influence on proliferation and was generally less pronounced in mutant cells than in wild-type cells. The average number of apoptotic cells after treatment with afatinib was 2.6 times as high as the corresponding value following treatment with gefitinib (P<0.01). Levels of pEGFR, pHER-2, pERK, and pAKT were reduced more extensively by afatinib than by gefitinib (P<0.001). Some KRAS mutations (G12C/G12S/G12D) appear to weaken the activity of afatinib and gefitinib whereas others seem to increase sensitivity to treatment (G13D/G12A) compared with the parental clone (KRAS wild-type). In SW48 colorectal cancer cells, afatinib seems to be more potent than gefitinib because of its superior efficacy in inhibiting both EGFR and HER-2, suppressing signaling along both MEK/ERK and PI3K/AKT pathways to a greater extent.
- 20 January 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (3_suppl) , 672
Adjuvant treatment for resected rectal cancer: Effect of postoperative oxaliplatin added to 5-FU in the neoadjuvant era.
672 Background: Oxaliplatin (Ox) added to postoperative 5-fluorouracil (5FU) based adjuvant treatment has shown a survival benefit in colon cancer. For rectal cancer, the impact of Ox on survival has almost exclusively been tested in studies using 5FU +/- Ox both as a component of preoperative chemoradiotherapy (CRT) and as adjuvant treatment. Only one study (NCT00807911) investigated adjuvant 5FU +/- Ox in patients undergoing preop 5FU based CRT without Ox. Thus, the evidence for the benefit of adding Ox to adjuvant 5FU in patients treated with preop 5FU based CRT is limited. Methods: Data from the prospective German multicenter Quality Assurance in Rectal Cancer observational trial involving more than 300 hospitals of all levels of care throughout Germany were retrospectively analyzed. Patients undergoing R0 total mesorectal excision (TME) for rectal cancer following neoadjuvant 5FU based treatment without oxaliplatin between 01/01/2008 and 12/31/2010 were included. Disease-free survival (DFS) in patients receiving adjuvant treatment with or without Ox was compared using the Kaplan Meier method. The impact of adjuvant treatment with 5FU with or without Ox on DFS was investigated in a Cox regression analysis including open vs. laparoscopic approach, pT stage, pN stage, tumor grading, TME quality grade, and presence of anastomotic leakage as potential confounding factors. Results: The entire data set included 1,861 patients. Data for all variables investigated were available for 599 patients of whom 512 (85%) and 89 (15%) received 5FU based adjuvant treatment without and with Ox, respectively. Mean DFS was not different in patients receiving 5FU only vs. 5FU with Ox (p=0.103). Cox regression analysis revealed no significant impact of adding Ox to adjuvant 5FU on DFS. Of all factors analyzed, only pN2 (vs. pN0) status had an independent adverse effect on DFS (Hazard ratio 4.22, p
- 20 January 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (3_suppl) , 672
Adjuvant treatment for resected rectal cancer: Effect of postoperative oxaliplatin added to 5-FU in the neoadjuvant era.
672 Background: Oxaliplatin (Ox) added to postoperative 5-fluorouracil (5FU) based adjuvant treatment has shown a survival benefit in colon cancer. For rectal cancer, the impact of Ox on survival has almost exclusively been tested in studies using 5FU +/- Ox both as a component of preoperative chemoradiotherapy (CRT) and as adjuvant treatment. Only one study (NCT00807911) investigated adjuvant 5FU +/- Ox in patients undergoing preop 5FU based CRT without Ox. Thus, the evidence for the benefit of adding Ox to adjuvant 5FU in patients treated with preop 5FU based CRT is limited. Methods: Data from the prospective German multicenter Quality Assurance in Rectal Cancer observational trial involving more than 300 hospitals of all levels of care throughout Germany were retrospectively analyzed. Patients undergoing R0 total mesorectal excision (TME) for rectal cancer following neoadjuvant 5FU based treatment without oxaliplatin between 01/01/2008 and 12/31/2010 were included. Disease-free survival (DFS) in patients receiving adjuvant treatment with or without Ox was compared using the Kaplan Meier method. The impact of adjuvant treatment with 5FU with or without Ox on DFS was investigated in a Cox regression analysis including open vs. laparoscopic approach, pT stage, pN stage, tumor grading, TME quality grade, and presence of anastomotic leakage as potential confounding factors. Results: The entire data set included 1,861 patients. Data for all variables investigated were available for 599 patients of whom 512 (85%) and 89 (15%) received 5FU based adjuvant treatment without and with Ox, respectively. Mean DFS was not different in patients receiving 5FU only vs. 5FU with Ox (p=0.103). Cox regression analysis revealed no significant impact of adding Ox to adjuvant 5FU on DFS. Of all factors analyzed, only pN2 (vs. pN0) status had an independent adverse effect on DFS (Hazard ratio 4.22, p
- 11 October 2013
- Published by Springer Nature in Der Chirurg
- Vol. 84 (10) , 833-834
Chirurgie und Lehre
- 11 October 2013
- Published by Springer Nature in Der Chirurg
- Vol. 84 (10) , 833-834
Chirurgie und Lehre
- 8 July 2013
- Published by Georg Thieme Verlag KG in Zentralblatt fur Chirurgie
- Vol. 140 (03) , 294-303
Bedeutung mesenchymaler Stammzellen in der Viszeralmedizin
In dieser Übersichtsarbeit wird der aktuelle Stand der experimentellen und klinischen Anwendung mesenchymaler Stammzellen (MSCs) in der Viszeralmedizin dargestellt. Neben dem Einsatz im regenerativen und immunologischen Kontext weckt diese Zellpopulation ebenso große Erwartungen im Bereich der Tumortherapie. Während in klinischen Studien zu chronisch-entzündlichen Darmerkrankungen und degenerativen Leberschäden bereits ein günstiger Effekt mesenchymaler Stammzellen demonstriert werden konnte, bildet die recht gegensätzliche Studienlage zu gastrointestinalen Tumoren das Potenzial anti-neoplastischer Therapieansätze durch MSCs noch nicht zufriedenstellend ab. Mesenchymale Stammzellen verfügen über ein breites Differenzierungspotenzial und sind in der Lage, über para- und endokrine Mechanismen den Vorgang der Wundheilung zu beeinflussen und immunologische Prozesse zu regulieren. Weiterhin bieten sie nach Transfektion die Möglichkeit einer zellbasierten Gentherapie. Zusammen mit der Fähigkeit zur tumorgerichteten Migration ergibt sich damit die Option einer gezielten Behandlung solider Tumoren mittels lokal exprimierter Substanzen, die zur Apoptose von Tumorzellen führen kann. In Hinblick auf die Vielfalt therapeutischer Optionen wird in dieser Übersichtsarbeit die Distribution exogen zugeführter MSCs im Organismus erläutert, die Möglichkeit einer Visualisierung der Verteilungsdynamik diskutiert und die Bedeutung unterschiedlicher Applikationsformen geklärt. Abschließend werden die Risiken mesenchymaler Stammzellen und damit die derzeitige Zurückhaltung der breiten klinischen Anwendung dargelegt. In this review we summarise the recent developments regarding the experimental and clinical use of mesenchymal stem cells (MSCs), focusing mainly on the treatment of gastrointestinal disorders. Next to their relevance in the field of regenerative medicine and immunology, this population of cells has also raised great expectations for possible applications in cancer therapy. While clinical trials were able to demonstrate the efficacy of MSCs in cases of inflammatory bowel disease and degenerative conditions of the liver, controversial results have been presented regarding their antineoplastic potential in gastrointestinal tumours. MSCs can differentiate into a large variety of specialised cells. They are capable of regulating both wound healing and immune responses through paracrine and endocrine signalling. Moreover, MSCs can be transfected with a great number of different therapeutic genes – considering their ability to selectively migrate towards neoplastic tissues, this feature allows for targeted therapy of solid tumours. Transfected genes can be designed so that they are expressed exclusively in the vicinity of the tumour, eventually triggering apoptosis in cancer cells. In this review, we demonstrate the natural distribution of exogenously applied MSCs in the host. Furthermore, we mention various methods of tracking MSCs in vivo and different parameters of administration that tend to influence therapeutic outcome (e.g., origin of MSCs, mode of application, or the potency of transfected genes). Finally, this review points out the hazards of MSC therapy, emphasising the risks related to their widespread clinical use.
- 8 July 2013
- Published by Georg Thieme Verlag KG in Zentralblatt fur Chirurgie
- Vol. 140 (03) , 294-303
Bedeutung mesenchymaler Stammzellen in der Viszeralmedizin
In dieser Übersichtsarbeit wird der aktuelle Stand der experimentellen und klinischen Anwendung mesenchymaler Stammzellen (MSCs) in der Viszeralmedizin dargestellt. Neben dem Einsatz im regenerativen und immunologischen Kontext weckt diese Zellpopulation ebenso große Erwartungen im Bereich der Tumortherapie. Während in klinischen Studien zu chronisch-entzündlichen Darmerkrankungen und degenerativen Leberschäden bereits ein günstiger Effekt mesenchymaler Stammzellen demonstriert werden konnte, bildet die recht gegensätzliche Studienlage zu gastrointestinalen Tumoren das Potenzial anti-neoplastischer Therapieansätze durch MSCs noch nicht zufriedenstellend ab. Mesenchymale Stammzellen verfügen über ein breites Differenzierungspotenzial und sind in der Lage, über para- und endokrine Mechanismen den Vorgang der Wundheilung zu beeinflussen und immunologische Prozesse zu regulieren. Weiterhin bieten sie nach Transfektion die Möglichkeit einer zellbasierten Gentherapie. Zusammen mit der Fähigkeit zur tumorgerichteten Migration ergibt sich damit die Option einer gezielten Behandlung solider Tumoren mittels lokal exprimierter Substanzen, die zur Apoptose von Tumorzellen führen kann. In Hinblick auf die Vielfalt therapeutischer Optionen wird in dieser Übersichtsarbeit die Distribution exogen zugeführter MSCs im Organismus erläutert, die Möglichkeit einer Visualisierung der Verteilungsdynamik diskutiert und die Bedeutung unterschiedlicher Applikationsformen geklärt. Abschließend werden die Risiken mesenchymaler Stammzellen und damit die derzeitige Zurückhaltung der breiten klinischen Anwendung dargelegt. In this review we summarise the recent developments regarding the experimental and clinical use of mesenchymal stem cells (MSCs), focusing mainly on the treatment of gastrointestinal disorders. Next to their relevance in the field of regenerative medicine and immunology, this population of cells has also raised great expectations for possible applications in cancer therapy. While clinical trials were able to demonstrate the efficacy of MSCs in cases of inflammatory bowel disease and degenerative conditions of the liver, controversial results have been presented regarding their antineoplastic potential in gastrointestinal tumours. MSCs can differentiate into a large variety of specialised cells. They are capable of regulating both wound healing and immune responses through paracrine and endocrine signalling. Moreover, MSCs can be transfected with a great number of different therapeutic genes – considering their ability to selectively migrate towards neoplastic tissues, this feature allows for targeted therapy of solid tumours. Transfected genes can be designed so that they are expressed exclusively in the vicinity of the tumour, eventually triggering apoptosis in cancer cells. In this review, we demonstrate the natural distribution of exogenously applied MSCs in the host. Furthermore, we mention various methods of tracking MSCs in vivo and different parameters of administration that tend to influence therapeutic outcome (e.g., origin of MSCs, mode of application, or the potency of transfected genes). Finally, this review points out the hazards of MSC therapy, emphasising the risks related to their widespread clinical use.
- 13 June 2013
- Published by Springer Nature in Der Chirurg
- Vol. 84 (6) , 522
Erratum zu: Pankreaskarzinom im hohen Alter
- 13 June 2013
- Published by Springer Nature in Der Chirurg
- Vol. 84 (6) , 522
Erratum zu: Pankreaskarzinom im hohen Alter
- 1 April 2013
- Published by S. Karger AG in Visceral Medicine
- Vol. 29 (2) , 113-119
Hepatozelluläres Karzinom - ein interdisziplinäres Krankheitsbild
- 1 April 2013
- Published by S. Karger AG in Visceral Medicine
- Vol. 29 (2) , 113-119
Hepatozelluläres Karzinom - ein interdisziplinäres Krankheitsbild
- 13 March 2013
- Published by Springer Nature in Der Chirurg
- Vol. 84 (4) , 291-295
Pankreaskarzinom im hohen Alter
- 13 March 2013
- Published by Springer Nature in Der Chirurg
- Vol. 84 (4) , 291-295
Pankreaskarzinom im hohen Alter
- 27 January 2013
- Published by Springer Nature in Der Chirurg
- Vol. 84 (2) , 97-98
Chronische Pankreatitis
- 27 January 2013
- Published by Springer Nature in Der Chirurg
- Vol. 84 (2) , 97-98
Chronische Pankreatitis
- 11 August 2012
- Published by Springer Nature in Der Chirurg
- Vol. 83 (8) , 696-697
Adenokarzinome des ösophagogastralen Übergangs
- 11 August 2012
- Published by Springer Nature in Der Chirurg
- Vol. 83 (8) , 696-697
Adenokarzinome des ösophagogastralen Übergangs
- 1 July 2012
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 94 (1) , 293-295
Thoracoscopic Resection of a Giant Midesophageal Diverticulum
- 1 July 2012
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 94 (1) , 293-295
Thoracoscopic Resection of a Giant Midesophageal Diverticulum